Form 8-K - Current report:
SEC Accession No. 0001493152-24-039392
Filing Date
2024-10-03
Accepted
2024-10-03 16:36:56
Documents
16
Period of Report
2024-09-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 53627
2 ex2-1.htm EX-2.1 25508
3 ex10-1.htm EX-10.1 294587
4 ex10-2.htm EX-10.2 226110
  Complete submission text file 0001493152-24-039392.txt   892173

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE evfm-20240927.xsd EX-101.SCH 3009
6 XBRL LABEL FILE evfm-20240927_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE evfm-20240927_pre.xml EX-101.PRE 24161
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3587
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 241352039
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)